Cervical Lymphatico-Venous Bypass for Treatment of Alzheimer's Disease - Proof of Concept
Alzheimer's disease (AD), one of the most common causes of dementia in Singapore and the developed world, is a neurodegenerative disorder with high socioeconomic impact. Accumulation of neurotoxic proteins (ie. amyloid, tau) are purported to lead to neuroinflammation, synaptic dysfunction and cognitive decline. The ava
| Condition(s) | Alzheimer Disease, Dementia Alzheimer Type, Dementia Alzheimer's Type, Alzheimer's Disease, Alzheimer's Disease (AD) |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Alzheimer's disease (AD), one of the most common causes of dementia in Singapore and the developed world, is a neurodegenerative disorder with high socioeconomic impact. Accumulation of neurotoxic proteins (ie. amyloid, tau) are purported to lead to neuroinflammation, synaptic dysfunction and cognitive decline. The available pharmacotherapy provide limited symptomatic control, modest effect on disease progression with significant risk of side effects. Patients with AD eventually run out of effective pharmacotherapy and deteriorate. Recent evidence implicated the glymphatic system, meningeal lymphatics of the brain, and downstream drainage to the cervical lymphatic system in the accumulation of neurotoxic proteins in AD. This presented the opportunity for extra-cranial intervention, and has |
| Who can participate | Inclusion Criteria: * Diagnosis of mild-moderate Alzheimer's disease (based on NIA-AA criteria); * Mini-Mental State Examination (MMSE) score 10-22; * Both participants and caregiver are able to understand English or Mandarin * Ability to provide informed consent or have a legally authorised representative to provide informed consent; * Good family support for post-treatment care and rehabilitation; * Fit for general anaesthesia/deep sedation and surgery (ASA 1-2; excluding the diagnosis of Alzheimer's Disease). Exclusion Criteria: * Cognitive decline due to prior infection or autoimmune diseases; * History of major cerebrovascular events or significant cardiovascular diseases; * Inability to have the head turned passively by at least 40 degrees; * Previous neck lymph node surgery or irrad |
| Ages | 50 Years to 80 Years |
| Sex | All |
| Lead sponsor | Vincent Tay Khwee Soon |
| Locations | Singapore, Singapore |
| Start date | 2025-04-01 |
| NCT ID | NCT06965062 |
| Official listing | https://clinicaltrials.gov/study/NCT06965062 |